12:22 PM EST, 03/05/2025 (MT Newswires) -- Moderna ( MRNA ) continues to expect potential approval of its investigational individualized neoantigen therapy, or INT, by 2027, President Stephen Hoge said at an investor conference Wednesday according to a FactSet transcript.

The investigational therapy, which is being developed in partnership with Merck ( MRK ) , is being evaluated in a phase 3 trial that is fully enrolled.

"We're cautiously optimistic that 2027 is right on path," Hoge said, according to the transcript.

Hoge said Moderna ( MRNA ) and Merck ( MRK ) have not yet guided to pricing, but he said they believe INT could become a large revenue opportunity that could grow quickly as the company expands the indications.

Hoge also said the company is moving forward with phase 3 trials of its bird flu vaccine in the US. "We still believe that that's prudent (to have countermeasures) from a public health perspective," Hoge said, according to the transcript.

Shares of Moderna ( MRNA ) were up more than 5% in recent trading.

Price: 31.99, Change: +1.62, Percent Change: +5.32